InspireMD Q3 revenue record $1.81M (+16.3% YoY); net loss $7.89M; submits PMA to FDA for CGuard Prime

InspireMD, Inc.

2024-Q3 EPS reported -$0.58 revenue$5,060,000

Revenue record $1.81M, up 16.3% YoY; gross margin 22.9% down from 28.1% due to higher costs.
Net loss $7.89M ($0.16/share) vs $5.18M ($0.15/share) in Q3 2023; operating expenses rose 46% to $8.88M.
Submitted PMA to FDA for CGuard Prime carotid stent; targets U.S. approval in H1 2025.
IDE approved for CGUARDIANS II pivotal study of CGuard Prime for TCAR procedures.
Cash and marketable securities $40.4M at Sept 30, 2024; new Miami HQ to support U.S. launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.